Standard Biotools (LAB) Cash from Operations Growth (3y) (2013 - 2026)
Standard Biotools (LAB) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 186.78 Bn | 179.48 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 131.95 Bn | 129.07 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 111.27 Bn | 102.05 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 68.58 Bn | 67.13 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 48.31 Bn | 44.63 Bn | 1.29 Bn | -48.14% |
| 6 | GE HealthCare Technologies | 29.23 Bn | 26.94 Bn | 1.98 Bn | -14.75% |
| 7 | Dexcom | 28.90 Bn | 27.78 Bn | 750.30 Mn | 50.11% |
| 8 | Smith & Nephew | 28.19 Bn | 27.62 Bn | - | - |
| 9 | Koninklijke Philips | 24.33 Bn | 21.29 Bn | 2.01 Bn | -2.37% |
| 10 | Standard Biotools | 305.20 Mn | -149.97 Mn | 11.31 Mn | -76.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76.43% |
| Dec 31, 2025 | 60.41% |
| Sep 30, 2025 | 3.38% |
| Jun 30, 2025 | 11.67% |
| Mar 31, 2025 | -24.77% |
| Sep 30, 2024 | 9.06% |
| Jun 30, 2024 | -12.31% |
| Mar 31, 2024 | -69.19% |
| Dec 31, 2023 | -55.59% |
| Sep 30, 2023 | -35.38% |
| Jun 30, 2023 | -49.54% |
| Mar 31, 2023 | -25.48% |
| Dec 31, 2022 | -51.47% |
| Sep 30, 2022 | -75.56% |
| Jun 30, 2022 | -81.53% |
| Mar 31, 2022 | 8.17% |
| Sep 30, 2021 | -108.92% |
| Jun 30, 2021 | -85.43% |
| Mar 31, 2021 | 7.26% |
| Dec 31, 2020 | -97.02% |